Abstract
To investigate the effect of natural pyrazinamidase (PncA) mutations on protein function, we analyzed expression and PncA activity of eight pncA point mutants identified in nineteen pyrazinamide-resistant Mycobacterium tuberculosis clinical isolates. Among them, two mutants (Y99D and T135P) showed high expression level and solubility comparable to those of the wild-type PncA protein, two (K48E and G97D) displayed low expression level and solubility, and four (C14R, H51P, W68S, and A146V) were insoluble. Interestingly, when possible structural effects of these mutations were predicted by the CUPSAT program based on the proposed three-dimensional structure of M. tuberculosis PncA, only two highly soluble mutant proteins (Y99D and T135P) were predicted to be stabilizing and have favorable torsion angles. However, the others exhibiting either low solubility or precipitation were foreseen to be destabilizing and/or have unfavorable torsion angles, suggesting that the alterations could interfere with proper protein folding, thereby decreasing or depleting protein solubility. A PncA activity assay demonstrated that two mutants (G97D and T135P) showed virtually no activity, but two other mutants (K48E and Y99D) exhibited wild-type activity, indicating that the PncA residues (Cys14, His51, Trp68, Gly97, Thr135, and Ala146) may be important for PncA activity and/or proper protein folding.
Similar content being viewed by others
References
Barco P, Cardoso RF, Hirata RD, Leite CQ, Pandolfi JR, Sato DN, Shikama ML, de Melo FF, Mamizuka EM, Campanerut PA, Hirata MH (2006) pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis clinical isolates from the southeast region of Brazil. J Antimicrob Chemother 58:930–935
Cheng SJ, Thibert L, Sanchez T, Heifets L, Zhang Y (2000) pncA mutations as a major mechanism of pyrazinamide resistance in Mycobacterium tuberculosis: spread of a monoresistant strain in Quebec, Canada. Antimicrob Agents Chemother 44:528–532
Du X, Wang W, Kim R, Yakota H, Nguyen H, Kim SH (2001) Crystal structure and mechanism of catalysis of a pyrazinamidase from Pyrococcus horikoshii. Biochemistry 40:14166–14172
Escalante P, Ramaswamy S, Sanabria H, Soini H, Pan X, Valiente-Castillo O, Musser JM (1998) Genotypic characterization of drug-resistant Mycobacterium tuberculosis isolates from Peru. Tuber Lung Dis 79:111–118
Fyfe PK, Rao VA, Zemla A, Cameron S, Hunter WN (2009) Specificity and mechanism of Acinetobacter baumanii nicotinamidase: implications for activation of the front-line tuberculosis drug pyrazinamide. Angew Chem Int Ed Engl 48:9176–9179
Goldstone RM, Moreland NJ, Bashiri G, Baker EN, Shaun Lott J (2008) A new Gateway vector and expression protocol for fast and efficient recombinant protein expression in Mycobacterium smegmatis. Protein Expr Purif 57:81–87
Heifets L, Lindholm-Levy P (1992) Pyrazinamide sterilizing activity in vitro against semidormant Mycobacterium tuberculosis bacterial populations. Am Rev Respir Dis 145:1223–1225
Hirano K, Takahashi M, Kazumi Y, Fukasawa Y, Abe C (1997) Mutation in pncA is a major mechanism of pyrazinamide resistance in Mycobacterium tuberculosis. Tuber Lung Dis 78:117–122
Huang TS, Lee SS, Tu HZ, Huang WK, Chen YS, Huang CK, Wann SR, Lin HH, Liu YC (2003) Correlation between pyrazinamide activity and pncA mutations in Mycobacterium tuberculosis isolates in Taiwan. Antimicrob Agents Chemother 47:3672–3673
Jonmalung J, Prammananan T, Leechawengwongs M, Chaiprasert A (2010) Surveillance of pyrazinamide susceptibility among multidrug-resistant Mycobacterium tuberculosis isolates from Siriraj Hospital, Thailand. BMC Microbiol 10:223
Lee KW, Lee JM, Jung KS (2001) Characterization of pncA mutations of pyrazinamide-resistant Mycobacterium tuberculosis in Korea. J Korean Med Sci 16:537–543
Lemaitre N, Sougakoff W, Truffot-Pernot C, Jarlier V (1999) Characterization of new mutations in pyrazinamide-resistant strains of Mycobacterium tuberculosis and identification of conserved regions important for the catalytic activity of the pyrazinamidase PncA. Antimicrob Agents Chemother 43:1761–1763
Lemaitre N, Callebaut I, Frenois F, Jarlier V, Sougakoff W (2001) Study of the structure-activity relationships for the pyrazinamidase (PncA) from Mycobacterium tuberculosis. Biochem J 353:453–458
Marttila HJ, Marjamäki M, Vyshnevskaya E, Vyshnevskiy BI, Otten TF, Vasilyef AV, Viljanen MK (1999) pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis isolates from northwestern Russia. Antimicrob Agents Chemother 43:1764–1766
Mirabal NC, Yzquierdo SL, Lemus D, Madruga M, Milián Y, Echemendía M, Takiff H, Martin A, Van der Stuyf P, Palomino JC, Montoro E (2010) Evaluation of colorimetric methods using nicotinamide for rapid detection of pyrazinamide resistance in Mycobacterium tuberculosis. J Clin Microbiol 48:2729–2733
Morlock GP, Crawford JT, Butler WR, Brim SE, Sikes D, Mazurek GH, Woodley CL, Cooksey RC (2000) Phenotypic characterization of pncA mutants of Mycobacterium tuberculosis. Antimicrob Agents Chemother 44:2291–2295
Murray MG, Thompson WF (1980) Rapid isolation of high molecular weight plant DNA. Nucleic Acids Res 8:4321–4325
Nam JS, Yoon JH, Lee HI, Kim SW, Ro YT (2011) Molecular cloning, purification, and characterization of a superoxide dismutase from a fast-growing Mycobacterium sp. Strain JC1 DSM 3803. J Microbiol 49:399–406
Parthiban V, Gromiha MM, Schomburg D (2006) CUPSAT: prediction of protein stability upon point mutations. Nucleic Acids Res 34:W239–242
Petrella S, Gelus-Ziental N, Maudry A, Laurans C, Boudjelloul R, Sougakoff W (2011) Crystal structure of the pyrazinamidase of Mycobacterium tuberculosis: insights into natural and acquired resistance to pyrazinamide. PLoS ONE 6:e15785
Portugal I, Barreiro L, Moniz-Pereira J, Brum L (2004) pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis isolates in Portugal. Antimicrob Agents Chemother 48:2736–2738
Quiliano M, Gutierrez AH, Gilman RH, López C, Evangelista W, Sotelo J, Sheen P, Zimic M (2011) Structure-activity relationship in mutated pyrazinamidases from Mycobacterium tuberculosis. Bioinformation 6:335–339
Sandgren A, Strong M, Muthukrishnan P, Weiner BK, Church GM, Murray MB (2009) Tuberculosis drug resistance mutation database. PLoS Med 6:e2
Scorpio A, Zhang Y (1996) Mutations in pncA, a gene encoding pyrazinamidase/nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus. Nat Med 2:662–667
Scorpio A, Lindholm-Levy P, Heifets L, Gilman R, Siddiqi S, Cynamon M, Zhang Y (1997) Characterization of pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother 41:540–543
Sheen P, Ferrer P, Gilman RH, López-Llano J, Fuentes P, Valencia E, Zimic MJ (2009) Effect of pyrazinamidase activity on pyrazinamide resistance in Mycobacterium tuberculosis. Tuberculosis (Edinb) 89:109–113
Snider DE, Graczyk J, Bek E, Rogowski J (1984) Supervised six-months treatment of newly diagnosed pulmonary tuberculosis using isoniazid, rifampin, and pyrazinamide with and without streptomycin. Am Rev Respir Dis 130:1091–1094
Sreevatsan S, Pan X, Zhang Y, Kreiswirth BN, Musser JM (1997) Mutations associated with pyrazinamide resistance in pncA of Mycobacterium tuberculosis complex organisms. Antimicrob Agents Chemother 41:636–640
Stoffels K, Mathys V, Fauville-Dufaux M, Wintjens R, Bifani P (2012) Systematic analysis of pyrazinamide-resistant spontaneous mutants and clinical isolates of Mycobacterium tuberculosis. Antimicrob Agents Chemother 56:5186–5193
Suzuki Y, Suzuki A, Tamaru A, Katsukawa C, Oda H (2002) Rapid detection of pyrazinamide-resistant Mycobacterium tuberculosis by a PCR-based in vitro system. J Clin Microbiol 40:501–507
Unissa AN, Selvakumar N, Hassan S (2009) Insight to pyrazinamide resistance in Mycobacterium tuberculosis by molecular docking. Bioinformation 4:24–29
Yoon JH, Nam JS, Kim KJ, Choi Y, Lee H, Cho SN, Ro YT (2011) Molecular characterization of drug-resistant and -susceptible Mycobacterium tuberculosis isolated from patients with tuberculosis in Korea. Diagn Microbiol Infect Dis 72:52–61
Zhang H, Deng JY, Bi LJ, Zhou YF, Zhang ZP, Zhang CG, Zhang Y, Zhang XE (2008) Characterization of Mycobacterium tuberculosis nicotinamidase/pyrazinamidase. FEBS J 275:753–762
Zhang H, Bi LJ, Li CY, Sun ZG, Deng JY, Zhang XE (2009) Mutations found in the pncA gene of Mycobacterium tuberculosis in clinical pyrazinamide-resistant isolates from a local region of China. J Int Med Res 37:1430–1435
Zimic M, Sheen P, Quiliano M, Gutierrez A, Gilman RH (2010) Peruvian and globally reported amino acid substitutions on the Mycobacterium tuberculosis pyrazinamidase suggest a conserved pattern of mutations associated to pyrazinamide resistance. Infect Genet Evol 10:346–349
Acknowledgments
This work was supported by Korea Science and Engineering Foundation (KOSEF) Grant R01-2008-000-12139-0 from the Korean Government (MEST).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Yoon, JH., Nam, JS., Kim, KJ. et al. Characterization of pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis isolates from Korea and analysis of the correlation between the mutations and pyrazinamidase activity. World J Microbiol Biotechnol 30, 2821–2828 (2014). https://doi.org/10.1007/s11274-014-1706-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11274-014-1706-0